Expanding the concept of drug lifecycle management to chimeric antigen receptor T-cell products through product-patent linkage analysis

IF 2.2 Q2 INFORMATION SCIENCE & LIBRARY SCIENCE

World Patent Information Pub Date : 2025-04-09 DOI:10.1016/j.wpi.2025.102357

Yasuaki Kawai, Shingo Kano

{"title":"Expanding the concept of drug lifecycle management to chimeric antigen receptor T-cell products through product-patent linkage analysis","authors":"Yasuaki Kawai, Shingo Kano","doi":"10.1016/j.wpi.2025.102357","DOIUrl":null,"url":null,"abstract":"<div><div>Chimeric antigen receptor T (CAR-T) cell therapies have been actively developed, and five CAR-T products have been commercialized in Japan. Due to the ongoing development of CAR-T cell therapies, including next-generation variants, the patent landscape is expected to become increasingly complex. Therefore, understanding patent strategies for each CAR-T product is essential.</div><div>In the pharmaceutical industry, lifecycle management (LCM) centered on regulatory and patent protection has been implemented to maximize product value. While studies have reported CAR-T patents through patent landscape analysis to gain insights into the overall CAR-T technology, there is a lack of research on product-related patents for CAR-T products. As a result, the foundational knowledge regarding the LCM of CAR-T products remains unclear.</div><div>Therefore, we identified product-patent linkages for CAR-T products in the Japanese market by combining patent term extension (PTE) data with publicly available data and assessed the applicability of drug LCM to CAR-T products. Our identification of precise product-patent linkages revealed that all CAR-T products met the criteria for drug LCM. This study suggests that LCM activities can be implemented for CAR-T products and that the concept of drug LCM can be expanded to CAR-T products.</div></div>","PeriodicalId":51794,"journal":{"name":"World Patent Information","volume":"81 ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Patent Information","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0172219025000249","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFORMATION SCIENCE & LIBRARY SCIENCE","Score":null,"Total":0}

引用次数: 0

Abstract

Chimeric antigen receptor T (CAR-T) cell therapies have been actively developed, and five CAR-T products have been commercialized in Japan. Due to the ongoing development of CAR-T cell therapies, including next-generation variants, the patent landscape is expected to become increasingly complex. Therefore, understanding patent strategies for each CAR-T product is essential.

In the pharmaceutical industry, lifecycle management (LCM) centered on regulatory and patent protection has been implemented to maximize product value. While studies have reported CAR-T patents through patent landscape analysis to gain insights into the overall CAR-T technology, there is a lack of research on product-related patents for CAR-T products. As a result, the foundational knowledge regarding the LCM of CAR-T products remains unclear.

Therefore, we identified product-patent linkages for CAR-T products in the Japanese market by combining patent term extension (PTE) data with publicly available data and assessed the applicability of drug LCM to CAR-T products. Our identification of precise product-patent linkages revealed that all CAR-T products met the criteria for drug LCM. This study suggests that LCM activities can be implemented for CAR-T products and that the concept of drug LCM can be expanded to CAR-T products.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

World Patent Information INFORMATION SCIENCE & LIBRARY SCIENCE-

CiteScore

3.50

自引率

18.50%

发文量

期刊介绍： The aim of World Patent Information is to provide a worldwide forum for the exchange of information between people working professionally in the field of Industrial Property information and documentation and to promote the widest possible use of the associated literature. Regular features include: papers concerned with all aspects of Industrial Property information and documentation; new regulations pertinent to Industrial Property information and documentation; short reports on relevant meetings and conferences; bibliographies, together with book and literature reviews.